Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
197.78 USD   -1.42%
09/22Truist Securities Adjusts Biogen's Price Target to $265 from $270, Maintains Buy Rating
MT
09/22UNIVERSITY OF SHEFFIELD : Promising MND drug helps slow disease progression and benefits patients physically
AQ
09/21The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen profit more than doubles on Samsung Bioepis stake sale

07/20/2022 | 07:09am EDT
FILE PHOTO: A sign marks a Biogen facility in Massachusetts

(Reuters) - Biogen Inc's second-quarter profit more than doubled on Wednesday, driven by a roughly $1.5-billion gain from the sale of its equity stake in the Samsung Bioepis Joint Venture.

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -1.42% 197.78 Delayed Quote.-17.56%
SAMSUNG ELECTRONICS CO., LTD. 0.18% 54500 End-of-day quote.-30.40%
All news about BIOGEN INC.
09/22Truist Securities Adjusts Biogen's Price Target to $265 from $270, Maintains Buy Rating
MT
09/22UNIVERSITY OF SHEFFIELD : Promising MND drug helps slow disease progression and benefits p..
AQ
09/21The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits ..
GL
09/21The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits ..
GL
09/20Boston Properties Acquires Laboratory, Life Sciences Property in Massachusetts From Bio..
MT
09/20STATEMENT : Biogen completes corporate real estate transaction to align its cambridge offi..
PU
09/20Boston Properties, Inc. acquired 125 Broadway, A six story 271,000 Square Foot Laborato..
CI
09/19Tysabri® (Natalizumab) Litigation Begins
AQ
09/12Stifel Nicolaus Lowers Biogen's Price Target to $223 From $230, Maintains Hold Rating
MT
09/12TRANSCRIPT : Biogen Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conferen..
CI
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 006 M - -
Net income 2022 2 340 M - -
Net cash 2022 11,0 M - -
P/E ratio 2022 12,4x
Yield 2022 -
Capitalization 28 700 M 28 700 M -
EV / Sales 2022 2,87x
EV / Sales 2023 2,72x
Nbr of Employees 9 610
Free-Float 85,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 197,78 $
Average target price 237,57 $
Spread / Average Target 20,1%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-17.56%28 700
CSL LIMITED-4.33%87 783
SAMSUNG BIOLOGICS CO.,LTD.-14.73%38 653
WUXI BIOLOGICS (CAYMAN) INC.-49.86%25 210
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-31.77%19 085
BIOMARIN PHARMACEUTICAL INC.-3.97%15 736